NKILT Therapeutics
Founded 2021 · 9 employees on LinkedIn · 1 known investors
NKILT Therapeutics is a cell therapy biotech developing engineered immune cells, starting with natural killer (NK) cells, to target leukemias and solid tumors. It uses a proprietary Chimeric ILT-Receptor (CIR) binding technology to create off-the-shelf, allogeneic cancer treatments targeting the HLA-G immune checkpoint molecule.
Founders & leadership
NKILT Therapeutics was founded in 2021 by Henri Bayle.
HB
Henri BayleinFounder
Investors · 1
Competitors · 4
by search overlapNKore Biotherapeutics11 shared keywordsNKore BioTherapeutics is a cellular-based biotherapeutics company developing an allogeneic immunotherapy platform based on a proprietary method of activating natural killer (NK) cells, called Supercharged NK (sNK) cells. Its lead therapy, NK101, targets solid and blood cancers in adult and pediatric patients, with human clinical trials planned in the United States beginning in 2027.
Celularity6 shared keywordsCelularity is a regenerative and cellular medicine company developing and commercializing biomaterial products and allogeneic, cryopreserved cell therapies derived from the postpartum placenta to target age-related diseases. It operates its own integrated manufacturing, translational research, and biobanking facility for placenta-derived cellular medicines and advanced biomaterials.
Nok Therapeutics6 shared keywordsNOK Therapeutics is a biotech company developing autologous Natural Killer (NK) cell therapies for cancer treatment that avoid the need for lymphodepletion. The company is an early-stage oncology/immunotherapy business raising capital through a Regulation A+ pre-IPO offering.
Nkarta, Inc.6 shared keywordsNkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments. Its lead program, NKX019, targets the CD19 antigen for B cell-mediated autoimmune conditions such as lupus nephritis and systemic sclerosis.
Companies competing with NKILT Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does NKILT Therapeutics do?
- NKILT Therapeutics is a cell therapy biotech developing engineered immune cells, starting with natural killer (NK) cells, to target leukemias and solid tumors. It uses a proprietary Chimeric ILT-Receptor (CIR) binding technology to create off-the-shelf, allogeneic cancer treatments targeting the HLA-G immune checkpoint molecule.
- Who founded NKILT Therapeutics?
- NKILT Therapeutics was founded by Henri Bayle in 2021.
- Who are NKILT Therapeutics's investors?
- NKILT Therapeutics's investors include The Innovation Space.